NASDAQ: CRMDCormedix Inc Stock
$8.61+0.23 (+2.74%)
Updated Sep 2, 2026
CRMD Price
$8.61
Fair Value Price
N/A
Market Cap
$671.10M
52 Week Low
$6.13
52 Week High
$13.93
P/E
3.65x
P/B
1.46x
P/S
1.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$462.25M
Earnings
$187.17M
Gross Margin
82.8%
Operating Margin
44.6%
Profit Margin
40.5%
Debt to Equity
0.96
Operating Cash Flow
$254M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRMD Overview
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRMD
Ranked#100 of 463
Ranked#100 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.69 | A | |
| $110.43 | A | |
| $7.01 | A |
Be the first to know about important CRMD news, forecast changes, insider trades & much more!
CRMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRMD is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRMD is good value based on its earnings relative to its share price (3.65x), compared to the US market average (39.72x)
P/E vs Market Valuation
CRMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CRMD due diligence checks available for Premium users.
Valuation
CRMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
3.65x
Industry
15.29x
Market
39.72x
CRMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CRMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CRMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
5.6x
CRMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRMD's financial health
Profit margin
Revenue
$101.9M
Net Income
$26.0M
Profit Margin
25.5%
CRMD's Earnings (EBIT) of $206.17M... subscribe to Premium to read more.
Interest Coverage Financials
CRMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$904.1M
Liabilities
$443.2M
Debt to equity
0.96
CRMD's short-term assets ($480.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRMD's short-term assets ($480.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$86.2M
Investing
-$561.0k
Financing
-$7.1M
CRMD's operating cash flow ($253.94M)... subscribe to Premium to read more.
Debt Coverage Financials
CRMD vs Biotech Stocks
Cormedix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.